Sheppart Pratt Health System
Towson, Maryland, 21204, United States
NCT Number: NCT02810964
The purpose of this study is to determine if taking a sulforaphane nutraceutical versus a placebo will reduce symptoms of schizophrenia when used in addition to standard antipsychotic medications.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 2
Towson, Maryland, 21204, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Sulforaphane Nutraceutical 6 tablets by mouth daily
Other names: Avmacol®
Identical-appearing Placebo 6 tablets by mouth daily
Time frame: 16 weeks (week 2 to week 18)
The Positive and Negative Syndrome Scale (PANSS) measures psychiatric symptomatology, especially related to psychosis. The complete PANSS contains ratings for 30 symptoms, including 7 positive symptoms, 7 negative symptoms, and 16 general psychiatric symptoms. The severity of each symptom is rated on a scale ranging from 1 (minimal) to 7 (extreme); higher scores indicate increased symptomatology. Total PANSS scores include scores from all categories and range from 30 to 210 units on a scale.
Time frame: 18 weeks (week 0 to week 18)
The MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) Consensus Cognitive Battery (MCCB) is a standardized battery of 10 tests that measure 7 domains of cognitive performance: speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. Overall composite t-scores are calculated using scores from all subtests. A t-score of 50 (10) is the mean (standard deviation) of the relevant reference population. Higher values indicate better performance.
Time frame: 18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)
Time frame: 18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)
Time frame: 18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)
Time frame: 18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)
Time frame: 18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)
Time frame: 18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)
Sheppard Pratt Health System
Other
A Double-Blind Placebo-Controlled Trial of a Sulforaphane Nutraceutical to Reduce the Symptoms of Schizophrenia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01945333
Mental Disorders, Psychotic Disorders
Brooklyn, New York, United States
View Trial DetailsNCT00001486
Behavior, Behavioral Symptoms
Bethesda, Maryland, United States
View Trial DetailsNCT00942981
Mental Disorders, Psychotic Disorders
Bethesda, Maryland, United States
View Trial DetailsNCT06007105
Acute and Transient Psychotic Disorder, Bipolar Type I Disorder With Psychotic Symptoms
Blantyre, Southern Region, Malawi
View Trial Details